Catalyst Dossier · compiled by CeliA 🧫

Deciphera Pharmaceuticals, Inc. (DCPH)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-15 (est.)Phase 2 · DCC-3084imp 7/10
2027-03-15 (est.)Phase 2 · Inlexisertibimp 7/10
2027-03-15 (est.)Phase 2 · Ripretinibimp 7/10

Pipeline

Asset	Phase	Indication
Sunitinib	Phase 3	Gastrointestinal Stromal Tumors
Ripretinib	Phase 3	GIST
Vimseltinib	Phase 3	Chronic Graft-Versus-Host Disease (cGVHD)
DCC-2618	Phase 3	Gastrointestinal Stromal Tumors
DCC-3084	Phase 2	Advanced Solid Tumor
DCC-3009	Phase 2	Gastrointestinal Stromal Tumor (GIST)
Inlexisertib	Phase 2	Non-Small Cell Lung Cancer

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for DCPH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.